Lane HC - Search Results

1

Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.

Dodd LE, Proschan MA, Neuhaus J, Koopmeiners JS, Neaton J, Beigel JD, Barrett K, Lane HC, Davey RT Jr. Dodd LE, et al. Among authors: lane hc. J Infect Dis. 2016 Jun 15;213(12):1906-13. doi: 10.1093/infdis/jiw061. Epub 2016 Feb 11. J Infect Dis. 2016. PMID: 26908739 Free PMC article. Clinical Trial.

2

State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus.

Jahrling PB, Hensley LE, Barrett K, Lane HC, Davey RT. Jahrling PB, et al. Among authors: lane hc. J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S84-90. doi: 10.1093/infdis/jiv115. Epub 2015 May 9. J Infect Dis. 2015. PMID: 25957962 Free PMC article.

3

Laboratory methods in the diagnosis and prognostic staging of infection with human immunodeficiency virus type 1.

Davey RT Jr, Lane HC. Davey RT Jr, et al. Among authors: lane hc. Rev Infect Dis. 1990 Sep-Oct;12(5):912-30. doi: 10.1093/clinids/12.5.912. Rev Infect Dis. 1990. PMID: 2237133 Review.

4

A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.

Schnittman SM, Vogel S, Baseler M, Lane HC, Davey RT Jr. Schnittman SM, et al. Among authors: lane hc. J Infect Dis. 1994 May;169(5):981-9. doi: 10.1093/infdis/169.5.981. J Infect Dis. 1994. PMID: 7909550 Clinical Trial.

5

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.

ACTIV-3/TICO Bamlanivimab Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. ACTIV-3/TICO Bamlanivimab Study Group, et al. Among authors: lane hc. Ann Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21. Ann Intern Med. 2022. PMID: 34928698 Free PMC article. Clinical Trial.

6

Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial.

Kovacs JA, Bechtel C, Davey RT Jr, Falloon J, Polis MA, Walker RE, Metcalf JA, Davey V, Piscitelli SC, Baseler M, Dewar R, Salzman NP, Masur H, Lane HC. Kovacs JA, et al. Among authors: lane hc. J Infect Dis. 1996 Apr;173(4):840-8. doi: 10.1093/infdis/173.4.840. J Infect Dis. 1996. PMID: 8603961 Clinical Trial.

7

Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1.

Walker RE, Spooner KM, Kelly G, McCloskey RV, Woody JN, Falloon J, Baseler M, Piscitelli SC, Davey RT Jr, Polis MA, Kovacs JA, Masur H, Lane HC. Walker RE, et al. Among authors: lane hc. J Infect Dis. 1996 Jul;174(1):63-8. doi: 10.1093/infdis/174.1.63. J Infect Dis. 1996. PMID: 8656014

8

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons.

Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Fyfe G, Lane HC. Davey RT Jr, et al. Among authors: lane hc. J Infect Dis. 1997 Apr;175(4):781-9. doi: 10.1086/513971. J Infect Dis. 1997. PMID: 9086130

9

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection.

Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC. Davey RT Jr, et al. Among authors: lane hc. J Infect Dis. 1999 Apr;179(4):849-58. doi: 10.1086/314678. J Infect Dis. 1999. PMID: 10068580 Clinical Trial.

10

Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

Imamichi H, Crandall KA, Natarajan V, Jiang MK, Dewar RL, Berg S, Gaddam A, Bosche M, Metcalf JA, Davey RT Jr, Lane HC. Imamichi H, et al. Among authors: lane hc. J Infect Dis. 2001 Jan 1;183(1):36-50. doi: 10.1086/317641. Epub 2000 Dec 8. J Infect Dis. 2001. PMID: 11106537

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

466 results

Search Page

Filters